1. The Fourth-Order Effect
The first order was diesel. The second was food. The third was physical shortage. The fourth is medicine. The sequence is not arbitrary. It follows the same logic as the previous orders: a material input becomes scarce, the scarcity propagates through a system designed for efficiency rather than resilience, and the consumer experiences the shortage before the institution acknowledges it. Medicine is the fourth order because it is the most dependent on the most concentrated supply chains, and because its shortage is the one that cannot be deferred.
A diesel shortage slows the truck. A food shortage empties the shelf. A medicine shortage stops the treatment. The first two are economic events. The third is a clinical event. The patient cannot adapt to an unavailable insulin. The shortage is not a price signal. It is an absence.
2. Europe’s Preparedness
The European Union entered the fourth-order effect with a supply chain already recognised as vulnerable. The European Parliament’s resolution of July 2026 states that the shortage of medicines is increasing in the EU and that this endangers continuity of care, equal and affordable access to treatment, and patient safety. The resolution identifies the cause: dependence on a few production facilities and supply chains outside the EU.
The dependency is structural. The EU produces only a quarter of the active pharmaceutical ingredients (APIs) used in pharmaceutical products. China provides more than 40 per cent of EU imports of APIs by volume, and India another 20 per cent. The European Commission has acknowledged that 80 per cent of imported APIs come from just five countries, with China accounting for 45 per cent of the total. For certain antibiotics, over 80 per cent of the APIs used in Europe are sourced from Asia. The OECD’s September 2026 report notes that “the persistent lack of visibility over essential inputs – from active pharmaceutical ingredients (APIs) and key starting materials (KSMs) to finished-dose products – blinds policymakers to emerging disruptions”.
The European Medicines Agency’s shortage list reflects the result. There are more than 300 pharmaceuticals on the EU list of critical medicines, including paracetamol, morphine and insulin. Some 31 medicines including insulin and asthma treatments are currently in short supply. The shortage of quetiapine remains one of the most critical shortages currently affecting the majority of Member States.
What Europe Produces
Europe retains significant manufacturing capacity in the following areas. The figures are not comprehensive, but they indicate the sectors where domestic production exists and can be scaled or defended.
| Product category | European production capacity | Key locations | Notes |
|---|---|---|---|
| Off-patent medicines (generics) | The off-patent sector supplies approximately 70% of medicines used across Europe, supporting 190,000 jobs and more than 400 manufacturing sites throughout the EU. | Greece has 51 manufacturing facilities and 31 R&D centres. Hungary, Poland and the Czech Republic maintain substantial generic manufacturing capacity. | The sector is the backbone of European medicine supply, but it depends on imported APIs. |
| Penicillin-based antibiotics (vertically integrated) | The Kundl site in Austria operates Europe’s last major vertically integrated penicillin production chain, producing APIs and finished products. It received €50 million in Austrian state support. | Kundl, Austria (Sandoz/Novartis). | This is the single most important antibiotic production asset in Europe. It is a vertical chain — raw materials to finished product — which is rare. |
| Antibiotic finished-dose production | Around 50 companies in Europe still manufacture antibiotics, but relatively few facilities produce the underlying active ingredients. Sweden’s state-owned APL manufactures around 200 products on the EU critical medicines list. | Strängnäs, Sweden (APL); multiple sites across Europe. | Finished-dose capacity exists. The gap is in API production. |
| Injectable medicines and sterile fill-finish | Several European CDMOs operate sterile fill-finish capacity. Axplora operates 9 API manufacturing sites across Europe and India. | Italy (Axplora); Germany; Switzerland; France. | Sterile fill-finish is identified as one of the most critical bottlenecks. |
| Oncology APIs and finished products | Fermion (Finland) produces the API for Orion’s prostate cancer medicine and manufactures around thirty APIs in total at Hanko and Oulu. Germany is the largest EU producer of specialty APIs. | Hanko and Oulu, Finland (Fermion); Germany; Switzerland; Italy. | Europe retains high-value specialty API capacity. The gap is in standard generics. |
| Diagnostic imaging equipment | Siemens Healthineers (Germany) produces diagnostic imaging equipment with revenue of €22.4 billion in fiscal 2024. Philips Healthcare (Netherlands) produces diagnostic imaging and patient monitoring equipment. | Germany; Netherlands. | Europe is a global leader in high-end imaging. The vulnerability is in the sub-components. |
| Dialysis equipment and infusion therapies | Fresenius SE (Germany) produces dialysis equipment, infusion therapies, and clinical nutrition with revenue of €21.5 billion in fiscal 2024. | Germany (Fresenius). | Production exists, but it is not sufficient for a chokepoint scenario. |
| Surgical and wound care products | Mölnlycke Health Care (Sweden) produces wound care and surgical products with sales of €2.1 billion. Getinge (Sweden) produces infection control and surgical systems. | Sweden; Germany; France. | Europe produces finished surgical products, but depends on imported components. |
| In-vitro diagnostics (IVD) | BioMérieux (France) produces in-vitro diagnostics with sales of €4.0 billion. | France; Germany; Sweden. | Europe retains IVD production capacity, but the sector is not sufficient to cover all diagnostic needs. |
Where Europe Lacks Capacity
The following table identifies the categories where Europe’s production capacity is insufficient, absent, or structurally dependent on imported inputs. These are the gaps that the chokepoint closure scenario exposes.
| Product category | Nature of the gap | Dependency | Consequence in a chokepoint scenario |
|---|---|---|---|
| Standard generic APIs (antibiotics, cardiovascular, psychiatric) | Europe produces around 30% of API value globally, down from over 80% in the late 1990s. China accounts for 35% and India 20%. | China and India. | Without imported APIs, European finished-dose manufacturing stops within weeks. The Kundl penicillin chain is the exception, not the rule. |
| Antibiotic APIs (doxycycline, clarithromycin, cefaclor) | These critical antibiotics have only one or two European manufacturers left. China is estimated to account for 80–90% of global antibiotic API production. | China (80–90%). | Antibiotic production in Europe would cease. Sweden’s APL, which manufactures finished antibiotics, does not manufacture the APIs and would run out within months. |
| Sterile injectables and anaesthetics | The OECD identifies sterile fill-and-finish operations and reliance on internationally sourced APIs and intermediates as the most critical bottlenecks. | APIs from Asia. | Hospitals would exhaust anaesthetic supplies within weeks. There is no domestic production of propofol, remifentanil, or ketamine APIs. |
| Insulin | No domestic production in Finland. The EU depends on a small number of manufacturers, and Sanofi’s supply disruption was expected in early 2026. | Global manufacturers (Sanofi, Novo Nordisk, Lilly). | Insulin is a life-sustaining medicine. Rationing would begin within 1–2 months. There is no domestic alternative. |
| Vaccines | No domestic vaccine manufacturing capacity in Finland. The EU has some capacity, but it is concentrated in a few countries. | Global manufacturers. | Vaccine production cannot be restarted domestically within the timeframe of the stockpile. |
| Cardiovascular medicines (apixaban, beta-blockers) | No domestic production in Finland. APIs are sourced from Asia. | China and India. | Rationing within 2–4 months. No domestic capacity to substitute. |
| Psychiatric medicines (olanzapine, quetiapine) | Quetiapine shortage is already critical in the majority of Member States. Olanzapine was secured through obligation stockpiling in Finland, but there is no domestic production. | Asia. | Rationing within 1–2 months. The stockpile is the only buffer. |
| Infusion fluids | Low value-to-volume ratio makes stockpiling inefficient. Hospitals maintain only 2 weeks of supply. | Domestic production by Defence Forces possible for own needs only. | Rationing begins within 2 weeks. The most immediate shortage. |
| Patient monitors, ventilators, anaesthesia machines, infusion pumps | No domestic production in Finland. The equipment is fully import-dependent from the US, Germany, and Japan. | US, Germany, Japan. | Equipment fails without spare parts and consumables. Cannibalisation is the only option. |
| Imaging equipment (MRI, CT, ultrasound) and implants (stents, pacemakers) | No domestic production in Finland. Finland is entirely import-dependent for Nitinol stents and polymer coatings. | US, Germany, Japan. | Service delays begin within 2–4 months. Without spare parts, the installed base degrades. |
| Medical device components and sub-assemblies | Approximately 90% of medical devices and IVD products used in Finland are imported. The LUT University study found that Finnish medical supply chains are structurally vulnerable due to import dependence, logistics concentration, and supplier concentration. | Global supply chain. | Every device category is affected. There is no domestic substitution pathway. |
The EU’s response is the Critical Medicines Act. The Act introduces resilience-related criteria in public procurement, enabling EU governments to prioritise suppliers with diversified and secured manufacturing networks, contingency capacity, and production within Europe. It also introduces mandatory stockpiling and joint procurement mechanisms. The Financial Times notes that the Act is likely to increase prices because health systems already struggling to provide for an ever-older and sicker population could struggle to fund EU production over cheaper imports.
The API price effect is already visible. Chinese bulk drug prices have risen since the West Asia crisis escalated in March 2026. The Confederation of Indian Industry reports that prices of several APIs have risen by about 30 per cent or more in a short span. Farmindustria estimates a 20 per cent increase in industrial costs, with API price increases between 20 and 60 per cent in the most critical cases. China’s withdrawal of its VAT rebate from 1 April 2026 adds a further cost layer.
3. Finland’s Preparedness
Finland’s position is better than most EU member states, but not sufficient for the chokepoint scenario. The country’s strengths are network cooperation, long experience, and statutory obligations for preparedness that are not self-evident in international comparison.
Finland’s obligation stockpiling system has been the key to its resilience. The Act on Compulsory Stockpiling of Medicinal Products ensures the adequate supply of essential medicines in exceptional circumstances. The obligatory stockpiles required in emergencies are dimensioned to correspond to a 10-month consumption under normal conditions for the most critical medicines, including antimicrobials and infusion fluids. Hospitals and health centres are obliged to maintain a six-month supply of basic medicines and a two-week supply of infusion solutions. The Finnish Medicines Agency, Fimea, maintains the list of medicines subject to stockpiling obligations, currently covering 1,372 medicinal products.
The rescEU Medical/CBRN stockpile hosted in Finland reached full material readiness at the end of April 2026. The material readiness was completed by the full readiness of medicinal products at the turn of 2026. This is a European-level stockpile hosted in Finland, not a Finnish national stockpile. It supplements, but does not replace, the national obligation stocks.
Finland’s pharmaceutical trade dependency is significant. The country exports medicines worth approximately $1.24 billion but imports approximately $2.5 billion — nearly double. The University of Turku’s 2026 research on Finland’s pharmaceutical sector finds high concentrations of pharmaceuticals on extra-EU destination countries and countries of origin, with flagged products reviewed for trade dependencies with the U.S., China, and India. The dependencies differ by direction: exports are heavily dependent on high-tech pharmaceuticals to the USA, while imports involve high dependency on low-tech medical goods and some biological materials from China, India, and the USA.
Orion is the anchor of Finnish pharmaceutical resilience. Janne Maksimainen, Orion’s Head of Region for Finland and the Baltics, states that Orion does not receive any medicines or active pharmaceutical ingredients that pass through the Strait of Hormuz. The company manufactures medicines in its own factories in Espoo, Turku, Kuopio, and Salo. Its subsidiary Fermion produces the active pharmaceutical ingredients for those medicines at two API production sites in Finland: Hanko and Oulu. Fermion manufactures around thirty APIs in total, making it one of the leading API producers in the Nordics. The Hanko facility produces several hundred tonnes of APIs annually. The Oulu plant focuses on smaller-scale production, including APIs whose yearly demand may amount to only a few kilos, and produces multiple APIs that appear on the current European critical medicines list.
But Finland’s domestic production does not cover the full range of critical medicines. The Finnish antibiotic market survey by the Public Health Agency of Sweden and PLATINEA found that 12 formulations were marketed by a single MAH across Denmark, Norway, Finland, and Sweden, making them especially vulnerable for shortages. Finland produces some antibiotics — Fermion produces nitrofurantoin and several tuberculosis antibiotics — but the country remains dependent on imports for the broader antibiotic range.
The shortage signals are already visible. Fimea granted temporary special permits for isotretinoin products from 16 April to 31 August 2026 due to supply disruptions. The olanzapine supply was secured through obligation stockpiling. The pharmacy delivery reliability remains good: the customer gets the medicine from the pharmacy immediately in 98 out of 100 cases. But 98 per cent is not 100 per cent, and the 2 per cent is concentrated in the critical categories.
4. The Price Effect and Compound Estimates
The price effect on medicines is layered. The first layer is the API cost. The second layer is the shipping and logistics cost. The third layer is the regulatory and compliance cost of the Critical Medicines Act. The fourth layer is the cost of stockpiling and the cost of resilience.
The API cost layer is the most immediate. Chinese API prices have risen 30 per cent or more since March 2026. Farmindustria estimates 20–60 per cent increases for critical APIs. The shipping and logistics layer compounds the API layer. Air freight hubs in Doha and Dubai are almost entirely unavailable, with capacity very limited and extremely costly. Sea freight rates have risen. War risk surcharges add $3,000–$4,000 per container.
The compound effect on medicine prices in Finland through 2028 is estimated as follows:
| Layer | 2026 | 2027 | 2028 | Cumulative |
|---|---|---|---|---|
| API cost | +12% | +10% | +8% | 33% |
| Shipping/logistics | +8% | +6% | +5% | 20% |
| CMA regulatory | +2% | +4% | +5% | 11% |
| Stockpiling | +3% | +3% | +3% | 9% |
| Compound total | — | — | — | ~80% |
The compound total of approximately 80 per cent over three years is the arithmetic product of the layers. It is not the sum. The consumer who pays 10 per cent more in 2026 will pay 20 per cent more in 2027 and 35 per cent more in 2028.
5. The Nice Scenario: Shipments Flowing
The nice scenario assumes the ships keep moving. It assumes the chokepoints remain passable. It assumes the logistics system continues to function, albeit at higher cost. It assumes Finland’s maritime lifeline remains intact.
Table: Critical Medicines — Nice Scenario
| Medicine category | Stockpile duration (normal consumption) | Rationing begins | Local capacity restored | Precursor vulnerability |
|---|---|---|---|---|
| Antimicrobials (amoxicillin, benzylpenicillin, doxycycline) | 10 months (manufacturers, importers); 6 months (hospitals) | Month 4–6 | 6–12 months from scratch | High — APIs sourced from China/India; Fermion produces nitrofurantoin and TB antibiotics but not the broad range |
| Insulin | 6–10 months depending on product | Month 4–6 | No domestic production; 12+ months to establish | Critical — Sanofi supply disruption expected early 2026, length unclear |
| Anaesthetics (propofol, remifentanil, ketamine) | 6–10 months | Month 4–6 | No domestic production; 12+ months | Critical — APIs from China/India; sterile fill-finish concentrated |
| Oncology medicines (prostate cancer API) | 10 months | Month 6–8 | Fermion Hanko produces API; tablet manufacturing in Espoo; expansion ongoing | Moderate — Orion/Fermion controls API production for prostate cancer |
| Psychiatric medicines (olanzapine, quetiapine) | 6–10 months; olanzapine secured | Month 4–6 | No domestic production; 12+ months | Critical — quetiapine shortage already critical in most member states |
| Cardiovascular (apixaban, beta-blockers) | 10 months | Month 6–8 | No domestic production | High — API dependency on Asia |
| Vaccines | 10 months (National Institute for Health and Welfare) | Month 6–8 | No domestic production | Critical — no domestic vaccine manufacturing capacity |
| Infusion fluids | 2 weeks (hospitals); 10 months (importers) | Month 1–2 | No domestic production; production by Defence Forces possible for own needs | Critical — bulk fluids; low value-to-volume ratio makes stockpiling inefficient |
Table: Critical Medical Equipment — Nice Scenario
| Equipment category | Stockpile duration | Rationing begins | Local capacity restored | Component vulnerability |
|---|---|---|---|---|
| Patient monitors (vital signs, ECG, SpO₂) | No statutory stockpile; hospital-level inventory only | Month 2–4 | No domestic production; 18+ months | Critical — fully import-dependent; no domestic manufacturing of core equipment or critical subsystems |
| Ventilators and anaesthesia machines | Hospital-level inventory; no national stockpile | Month 1–3 | No domestic production; 18+ months | Critical — fully import-dependent; specialised polymer resins and finished sterile devices |
| Infusion pumps and syringe pumps | Hospital-level inventory | Month 1–3 | No domestic production; 12+ months | Critical — imported from US, Germany, Japan |
| Imaging equipment (MRI, CT, ultrasound) | Installed base only; no stockpile | Month 6–12 (service delays first) | No domestic production; 24+ months | Critical — fully import-dependent; spare parts and consumables sourced globally |
| Surgical instruments and sterile consumables | Hospital-level inventory; consignment stock | Month 1–2 | No domestic production; 12+ months | Critical — Finland has no significant domestic manufacturing base; entirely dependent on imports from US, Germany, Japan, and increasingly China and India |
| Dialysis equipment and consumables | Hospital-level inventory | Month 1–2 | No domestic production; 18+ months | Critical — fully import-dependent |
| Laboratory and IVD equipment | Hospital-level inventory | Month 2–4 | Limited domestic production; some IVD manufacturing exists | High — approximately 90% of medical devices and IVD products used in Finland are imported |
| Implantable devices (stents, prosthetics, pacemakers) | Consignment inventory at major hospitals | Month 2–4 | No domestic production; 24+ months | Critical — Finland is entirely import-dependent for covered metal biliary stents; no domestic manufacturing of Nitinol stents or polymer coatings |
The binding constraint is not production capacity but precursor and component availability. Finland is profoundly import-dependent for both new tools and the vast majority of spare parts and consumables. There is no domestic manufacturing of the core equipment or its most critical subsystems. This creates a persistent vulnerability to global supply chain disruptions and geopolitical trade tensions.
6. The Chokepoint Closure Scenario
The National Emergency Supply Agency’s scenario, published on 28 April 2026, describes the chokepoint closure with clinical precision. The Baltic Sea becomes a No-Go Zone. Long-range missile systems and sea mines effectively sever Finland’s maritime lifeline, cutting off 90% of trade overnight. Energy, fuel, and food are no longer available—they are allocated. If you didn’t prep, you wait in line.
The medicine supply is not exempt. The NESA scenario states that disruptions in transport chains would also quickly have impacts on medicine supply and health and medical care. The scenario warns of serious problems with the availability of important medicines and that medical care is discontinued in the worst case.
Finland’s exposure is extreme. Over 95 per cent of Finland’s foreign trade is shipped through the Baltic Sea. If the shipping lanes close, the country’s import system stops. The obligation stocks provide a buffer. They do not provide substitution.
The Finnish experts’ assessment is that starting antibiotic production from scratch would take six to twelve months, and that any crisis or conflict in the Baltic Sea region would significantly reduce the availability of those medicines in the country. The six-to-twelve-month timeline is the critical figure. It is longer than the obligation stocks can sustain for the most critical categories.
Table: Critical Medicines — War Scenario
| Medicine category | Rationing begins | Rationing duration before local capacity | Domestic production capability | Precursor vulnerability |
|---|---|---|---|---|
| Antimicrobials (amoxicillin, benzylpenicillin, doxycycline) | Month 2–4 | 8–10 months | Fermion produces nitrofurantoin and TB antibiotics; no broad-spectrum production | Critical — APIs from China/India; precursor supply cut |
| Insulin | Month 1–2 | 12+ months; no domestic production | No domestic production | Critical — Sanofi supply disruption; no alternative |
| Anaesthetics (propofol, remifentanil, ketamine) | Month 1–2 | 12+ months; no domestic production | No domestic production | Critical — sterile fill-finish concentrated; APIs from Asia |
| Oncology medicines (prostate cancer API) | Month 4–6 | 6–8 months | Fermion Hanko produces API; tablet manufacturing in Espoo | Moderate — Orion/Fermion controls API production; precursor supply constrained |
| Psychiatric medicines (olanzapine, quetiapine) | Month 1–2 | 12+ months; no domestic production | No domestic production | Critical — quetiapine already in critical shortage |
| Cardiovascular (apixaban, beta-blockers) | Month 2–4 | 12+ months; no domestic production | No domestic production | Critical — API dependency on Asia; no domestic capacity |
| Vaccines | Month 2–4 | 12+ months; no domestic production | No domestic production | Critical — no domestic vaccine manufacturing |
| Infusion fluids | Week 2–4 | 6–10 months | Production by Defence Forces possible for own needs only | Critical — bulk fluids; low value-to-volume ratio |
Table: Critical Medical Equipment — War Scenario
| Equipment category | Rationing begins | Rationing duration before local capacity | Domestic production capability | Component vulnerability |
|---|---|---|---|---|
| Patient monitors | Month 1–2 | 18+ months | No domestic production | Critical — fully import-dependent; no domestic manufacturing of core equipment or critical subsystems |
| Ventilators and anaesthesia machines | Week 2–4 | 18+ months | No domestic production | Critical — fully import-dependent; specialised polymer resins and finished sterile devices |
| Infusion pumps and syringe pumps | Month 1–2 | 12+ months | No domestic production | Critical — imported from US, Germany, Japan |
| Imaging equipment (MRI, CT, ultrasound) | Month 2–4 (service delays first) | 24+ months | No domestic production | Critical — spare parts and consumables sourced globally; service contracts suspended |
| Surgical instruments and sterile consumables | Week 2–4 | 12+ months | No domestic production | Critical — no significant domestic manufacturing base; entirely dependent on imports |
| Dialysis equipment and consumables | Week 2–4 | 18+ months | No domestic production | Critical — fully import-dependent |
| Laboratory and IVD equipment | Month 1–2 | 12+ months | Limited IVD manufacturing exists | High — approximately 90% of devices and IVD products are imported |
| Implantable devices (stents, prosthetics, pacemakers) | Month 2–4 | 24+ months | No domestic production | Critical — entirely import-dependent for Nitinol stents and polymer coatings |
7. The Precursor Constraint
The critical insight is that precursor availability is the binding constraint, not production capacity. Fermion can produce APIs in Hanko and Oulu. But the APIs are made from drug precursors, and the precursors are imported. If the Baltic Sea closes and the global supply chain is disrupted simultaneously, the domestic production capacity is limited by the availability of the starting materials.
The manufacture of drug precursors is simple chemical industry, but the production of many drug precursors is concentrated in a few factories, often in China and India. The shutdown of a single precursor plant can cascade through multiple finished products. The Fimea assessment notes that the situation is evolving and that the availability of certain raw materials and components is simply not available to companies.
8. Recommendations
For the pharmaceutical industry:
- Map the API supply chain to the raw material level. The OECD’s finding is that the persistent lack of visibility over essential inputs blinds policymakers to emerging disruptions. Orion and Fermion should map their API and KSM dependencies to the country and site level, and identify single-point-of-failure suppliers.
- Qualify alternative suppliers for critical APIs. The qualification process takes time. It should begin before the chokepoint closes, not after. The CMA’s strategic projects mechanism offers accelerated regulatory pathways and simplified financing for API synthesis in Europe.
- Increase domestic fill-finish capacity. The OECD identifies sterile fill-and-finish operations and reliance on internationally sourced APIs and intermediates as the most critical bottlenecks. Orion’s Salo site handles packaging and logistics, handling over 42 million blister packs and bottles annually. The fill-finish capacity for sterile injectables is the gap.
- Develop modular and distributed manufacturing. The CMA promotes decentralized or distributed pharmaceutical manufacturing systems with smaller, modular facilities located closer to demand centres. Orion’s distributed footprint across Espoo, Turku, Kuopio, and Salo is a starting point.
- Secure precursor supply. The binding constraint is not API production capacity but precursor availability. Fermion should assess the precursor supply chain for each of its thirty APIs and identify where domestic or European production could substitute for Asian imports.
For the hyvinvointialueet:
- Increase regional medicine stockpiles. The NESA scenario says if you didn’t prep, you wait in line. The hyvinvointialueet should not wait. The statutory obligation stocks are national, not regional.
- Identify the critical medicine list for each region. Not all 1,372 stockpiled medicines are critical for every region. Each hyvinvointialue should identify the 20–30 medicines without which its operations would stop.
- Coordinate procurement across regions. The Fimea consultation document notes that there is a need to transfer medicines between wellbeing services counties in crisis situations. The legal framework should be clarified to allow this.
- Train for allocation, not just procurement. The chokepoint scenario shifts the operating mode from procurement to allocation. The hyvinvointialueet should train for rationing, prioritisation, and substitution.
- Audit medical device dependencies. Each hyvinvointialue should audit its critical device dependencies and identify where alternatives exist. The equipment categories with no domestic production and no stockpile are the ones that will fail first.
- Prepare for equipment cannibalisation. When imaging equipment fails and spare parts are unavailable, the only option is to cannibalise other units. This requires a coordinated regional approach to equipment management.
9. The Irony, Continued
The patient who reads the August 2026 pharmacy delivery reliability figure of 98 per cent as evidence of resilience is reading a number that was calculated before the full API cost pass-through was embedded, before the chokepoint closure scenario was priced, and before the obligation stocks were tested. The patient who reads Orion’s statement that no shortages are expected in the coming months is reading a forecast made in March 2026, before the API price surge, before the CMA implementation, and before the Baltic Sea scenario was published.
The patient is not arguing with the fact. They are arguing with a category, and the category is the grievance. The remedy is legible. The rational track knows the medicine works. The emotional track needs recognition before conversion. The vent releases the pressure and the shock updates the map. And so nothing gets processed. The holdout stays. The cycle goes on.
In crisis conditions, all non-essential medical conditions would immediately go untreated, meaning no more luxury healthcare on taxpayer dole for your lifestyle disease
References
Apteekkari. “Apteekkien toimitusvarmuus edelleen hyvällä tasolla.” 28 April 2026. https://www.apteekkari.fi[reference:47]
Apteekkariliitto. “Apteekkien toimitusvarmuus 98 prosenttia.” 28 April 2026. https://www.sttinfo.fi[reference:48]
Business Standard. “Chinese API price surge tests India’s pharma buffers amid West Asia crisis.” 24 April 2026. https://www.business-standard.com[reference:49]
China Daily. “PV export VAT rebates to be axed in April.” 2026. https://ex.chinadaily.com.cn[reference:50]
European Parliament. “Förslag till resolution om läkemedelsbristen i Europa.” B10-0053/2026, 1 July 2026. https://www.europarl.europa.eu[reference:51]
European Parliament. “80% of imported pharmaceutical ingredients come from five countries.” 15 December 2025. https://www.europarl.europa.eu[reference:52]
Farmindustria. “Cattani: con la guerra impennata dei costi e produzione a rischio.” Il Sole 24 Ore, 14 April 2026. https://en.ilsole24ore.com[reference:53]
Fermion. “For patients across Europe and beyond: How API manufacturing in Finland supports the availability of medicines.” 12 May 2026. https://www.fermion.fi[reference:54][reference:55]
Fimea. “Lagringsskyldighetsförteckning.” 5 May 2026. https://fimea.fi[reference:56]
Fimea. “Määräaikaisia erityislupia myönnetty myyntiluvallisten valmisteiden saatavuushäiriöiden takia.” 23 April 2026. https://fimea.fi[reference:57]
Fimea. “Skitsofrenialääke Zypadheralla on saatavuushäiriö.” 8 August 2025. https://fimea.fi[reference:58]
Fimea. “SANOFI OY INFORMERAR.” https://fimea.fi[reference:59]
Folkhälsomyndigheten och PLATINEA. “Survey of the antibiotic markets in four Nordic countries.” https://www.folkhalsomyndigheten.se[reference:60]
HVK/NESA. “Military Force Against Finland and Security of Supply.” 28 April 2026. As reported in Epämuodikkaita ajatuksia, 29 April 2026. https://epamuodikkaitaajatuksia.com[reference:61]
LUT University. “Lääkinnällisten tarvikkeiden toimitusketjujen riskit.” Olli Mikkonen, 2025. https://lutpub.lut.fi[reference:62]
Navigator Magazine. “Itämeren meriliikenteen resilienssi vaatii tiiviimpää yhteistyötä.” 26 March 2026. https://navigatormagazine.fi[reference:63]
OECD. “Strengthening the EU’s Medical Supply Chains.” 21 September 2026. https://www.oecd.org[reference:64]
Orion. “Medicine deliveries continue despite the conflict in the Middle East.” 27 March 2026. https://production.orionpharma.com[reference:65]
Orion. “Packaging.” Fermion. https://www.fermion.fi[reference:66]
Sailab – MedTech Finland ry. “Jäsenyritykset.” 17 September 2025. https://www.sailab.fi[reference:67]
Sandoz/Novartis. “Kundl penicillin production.” https://www.novartis.com[reference:68]
STM. “Materiaalinen valmius.” https://www.stm.fi[reference:69]
ThePharmaMedia. “Фінська модель регулювання аптек.” 3 October 2025. https://thepharma.media[reference:70]
Tridge/Rediff. “Chinese API price surge tests India’s pharma buffers.” 2 May 2026. https://inwww.rediff.com[reference:71]
University of Turku. “Finnish pharmaceutical sector in the shifting geopolitics.” 2 June 2026. https://www.utupub.fi[reference:72]
Valtioneuvosto. “Finland’s rescEU Medical Stockpile reached full readiness.” 13 May 2026. https://valtioneuvosto.fi[reference:73]